



1647
PATENT


Case Docket No. GENENT.065A
Date: August 2, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : DeSavauge et al.
Appl. No. : 09/272,835
Filed : March 19, 1999
For : GFRALPHA3 AND ITS
USES
Examiner : Unknown
Group Art Unit : 1647

I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first class mail in
an envelope addressed to: Assistant Commissioner
for Patents, Washington, D.C. 20231, on

August 2, 2001
(Date)


Ginger R. Dreger, Reg. No. 33,055

TECH CENTER 1600/2900

AUG 09 2001

RECEIVED


TRANSMITTAL LETTER

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231
ATTENTION: APPLICATION BRANCH


Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) SEQUENCE SUBMISSION STATEMENT.
- (X) AMENDMENT DIRECTING ENTRY OF "SEQUENCE LISTING" INTO THE SPECIFICATION.
- (X) SUBSTITUTE SEQUENCE LISTING IN 19 PAGES AND DISKETTE CONTAINING SUBSTITUTE SEQUENCE LISTING IN ELECTRONIC FORM.
- (X) COPY OF NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES.
- (X) The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment, to Account No. 11-1410. A duplicate copy of this sheet is enclosed.
- (X) Return prepaid postcard.


Ginger R. Dreger
Registration No. 33,055
Attorney of Record

GENENT, 265A
GRD



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/272,835 03/19/99 DE. SPOVAK

P P1268R1

HM22/0710
KNOBE, MARTENS, OLSON & BEAR, LLP
600 NEWPORT CENTER DRIVE,
SIXTEENTH FLOOR
NEWPORT BEACH CA 92660-1990

EXAMINER

HAYES, P

ART UNIT

PAPER NUMBER

1047

10

DATE MAILED:

7/19/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

DOCKETED ON:	7-13-01
BY:	SN
VERIFIED BY:	TK
ACTION:	Notice to Comply
DUE DATE:	August 10, 2001
FINAL DEADLINE:	January 10, 2002
ATTY:	GRD
ATTORNEY VERIFICATION OF DUE DATE AND FINAL DEADLINE:	

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
272 09/26/83	09/26/83		835

EXAMINER	
ART UNIT	PAPER NUMBER
	15

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures and the enclosed CRF Diskette Problem Report. It should also be noted that 37 CFR 1.821 (a)(2)(c-d) states that *each sequence disclosed must appear separately in the "Sequence listing" and in the text of the description and claims* (i.e., where first mentioned in the specification). See MPEP 2431. For example, page 7 of the specification should identify the sequences represented in Figures 1, 3 & 4. It is also unclear what SEQ ID NOs: 18-20 represent. Page 7, line 36 is further inconsistent with pages 49 & 51 on what exactly SEQ ID NOs: 21-22 represent. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Any inquiry concerning this communication should be directed to Examiner Robert C. Hayes, Art Unit 1647, whose telephone number is 703-305-3132.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Robert C. Hayes, Ph.D.
July 6, 2001

Gary L. Kunz
GARY L. KUNZ
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE